MEDIFAST INC (MED) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:MED - US58470H1014 - Common Stock
11.68 USD
-0.12 (-1.02%)
11.68 USD
0 (0%)
MED gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 36 industry peers in the Personal Care Products industry. While MED has a great health rating, there are worries on its profitability. MED is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- MED had negative earnings in the past year.
- In the past year MED had a positive cash flow from operations.
- MED had positive earnings in each of the past 5 years.
- MED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of 0.09%, MED perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
- MED has a Return On Equity (0.12%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.09% | ||
| ROE | 0.12% | ||
| ROIC | N/A |
ROA(3y)26.08%
ROA(5y)31.33%
ROE(3y)47.66%
ROE(5y)57.89%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MED has a Profit Margin of 0.06%. This is comparable to the rest of the industry: MED outperforms 50.00% of its industry peers.
- In the last couple of years the Profit Margin of MED has declined.
- In the last couple of years the Operating Margin of MED has declined.
- MED has a better Gross Margin (72.44%) than 72.22% of its industry peers.
- MED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 0.06% | ||
| GM | 72.44% |
OM growth 3Y-38.9%
OM growth 5Y-24.01%
PM growth 3Y-68.15%
PM growth 5Y-49.83%
GM growth 3Y-0.04%
GM growth 5Y-0.38%
2. Health
2.1 Basic Checks
- MED does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for MED has been increased compared to 1 year ago.
- The number of shares outstanding for MED has been reduced compared to 5 years ago.
- MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 4.62 indicates that MED is not in any danger for bankruptcy at the moment.
- With an excellent Altman-Z score value of 4.62, MED belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
- MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.62 |
ROIC/WACCN/A
WACC8.82%
2.3 Liquidity
- MED has a Current Ratio of 4.45. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 4.45, MED belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
- MED has a Quick Ratio of 3.95. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.
- MED's Quick ratio of 3.95 is amongst the best of the industry. MED outperforms 86.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.45 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
- MED shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -100.00%.
- The earnings per share for MED have been decreasing by -20.59% on average. This is quite bad
- MED shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -36.29%.
- MED shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.33% yearly.
EPS 1Y (TTM)-100%
EPS 3Y-47.33%
EPS 5Y-20.59%
EPS Q2Q%-160%
Revenue 1Y (TTM)-36.29%
Revenue growth 3Y-26.64%
Revenue growth 5Y-3.33%
Sales Q2Q%-36.21%
3.2 Future
- The Earnings Per Share is expected to decrease by -43.69% on average over the next years. This is quite bad
- MED is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -23.25% yearly.
EPS Next Y-78.11%
EPS Next 2Y-43.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-36.56%
Revenue Next 2Y-23.25%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- MED is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- MED's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 198.7 | ||
| EV/EBITDA | -14.7 |
4.3 Compensation for Growth
- MED's earnings are expected to decrease with -43.69% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-43.69%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 9.97%, MED is a good candidate for dividend investing.
- MED's Dividend Yield is rather good when compared to the industry average which is at 2.04. MED pays more dividend than 97.22% of the companies in the same industry.
- MED's Dividend Yield is rather good when compared to the S&P500 average which is at 1.91.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 9.97% |
5.2 History
- The dividend of MED decreases each year by -53.42%.
- MED has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)-53.42%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- 78.63% of the earnings are spent on dividend by MED. This is not a sustainable payout ratio.
- The Dividend Rate of MED has been decling, while earnings will also be declining. This means the current dividend is most likely not sustainable.
DP78.63%
EPS Next 2Y-43.69%
EPS Next 3YN/A
11.68
-0.12 (-1.02%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)02-16 2026-02-16/amc
Inst Owners84.91%
Inst Owner Change-0.05%
Ins Owners3.3%
Ins Owner Change0%
Market Cap128.36M
Revenue(TTM)429.69M
Net Income(TTM)248.00K
Analysts46.67
Price Target15.3 (30.99%)
Short Float %18.76%
Short Ratio8.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 9.97% |
Yearly Dividend0.07
Dividend Growth(5Y)-53.42%
DP78.63%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.85%
Min EPS beat(2)46.69%
Max EPS beat(2)199.01%
EPS beat(4)4
Avg EPS beat(4)116.81%
Min EPS beat(4)46.69%
Max EPS beat(4)199.01%
EPS beat(8)6
Avg EPS beat(8)95.8%
EPS beat(12)10
Avg EPS beat(12)87.61%
EPS beat(16)13
Avg EPS beat(16)70.85%
Revenue beat(2)2
Avg Revenue beat(2)7.01%
Min Revenue beat(2)5.26%
Max Revenue beat(2)8.75%
Revenue beat(4)4
Avg Revenue beat(4)5.3%
Min Revenue beat(4)3.13%
Max Revenue beat(4)8.75%
Revenue beat(8)7
Avg Revenue beat(8)3.21%
Revenue beat(12)11
Avg Revenue beat(12)3.67%
Revenue beat(16)14
Avg Revenue beat(16)3.57%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-82.22%
EPS NY rev (1m)0%
EPS NY rev (3m)147.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.3 | ||
| P/FCF | 198.7 | ||
| P/OCF | 17.84 | ||
| P/B | 0.6 | ||
| P/tB | 0.6 | ||
| EV/EBITDA | -14.7 |
EPS(TTM)0
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)0.06
FCFY0.5%
OCF(TTM)0.65
OCFY5.6%
SpS39.1
BVpS19.54
TBVpS19.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.09% | ||
| ROE | 0.12% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 0.06% | ||
| GM | 72.44% | ||
| FCFM | 0.15% |
ROA(3y)26.08%
ROA(5y)31.33%
ROE(3y)47.66%
ROE(5y)57.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)57.45%
ROCE(5y)70.54%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-38.9%
OM growth 5Y-24.01%
PM growth 3Y-68.15%
PM growth 5Y-49.83%
GM growth 3Y-0.04%
GM growth 5Y-0.38%
F-Score5
Asset Turnover1.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 46.9% | ||
| Cap/Sales | 1.52% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 89.73% | ||
| Profit Quality | 260.48% | ||
| Current Ratio | 4.45 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 4.62 |
F-Score5
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)86.65%
Cap/Depr(5y)168.74%
Cap/Sales(3y)0.96%
Cap/Sales(5y)1.15%
Profit Quality(3y)359.98%
Profit Quality(5y)250.42%
High Growth Momentum
Growth
EPS 1Y (TTM)-100%
EPS 3Y-47.33%
EPS 5Y-20.59%
EPS Q2Q%-160%
EPS Next Y-78.11%
EPS Next 2Y-43.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-36.29%
Revenue growth 3Y-26.64%
Revenue growth 5Y-3.33%
Sales Q2Q%-36.21%
Revenue Next Year-36.56%
Revenue Next 2Y-23.25%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-120.14%
EBIT growth 3Y-55.18%
EBIT growth 5Y-26.54%
EBIT Next Year-105.07%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-99.63%
FCF growth 3Y-34.4%
FCF growth 5Y-25.51%
OCF growth 1Y-96.19%
OCF growth 3Y-36.26%
OCF growth 5Y-21.91%
MEDIFAST INC / MED FAQ
What is the ChartMill fundamental rating of MEDIFAST INC (MED) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MED.
Can you provide the valuation status for MEDIFAST INC?
ChartMill assigns a valuation rating of 1 / 10 to MEDIFAST INC (MED). This can be considered as Overvalued.
Can you provide the profitability details for MEDIFAST INC?
MEDIFAST INC (MED) has a profitability rating of 3 / 10.
Can you provide the financial health for MED stock?
The financial health rating of MEDIFAST INC (MED) is 9 / 10.